Drug Pricing Reform Gathers Steam (Part 2)
FDA Law Blog
SEPTEMBER 14, 2021
PART 1: MAXIMUM FAIR PRICE PAYMENT LIMITATION UNDER MEDICARE PARTS B AND D AND THE COMMERCIAL INSURANCE MARKET. Under all of these programs, patient co-insurance would be calculated based on the MFP so that patients receive the benefit of that price. The Part B rebate would exclude vaccines as well.
52 
Let's personalize your content